Vector Borne Diseases: Clinical Trials

32 trials for Vector Borne Diseases, newest first

ClinicalTrials Daily  ·  Areas  ·  Conditions  ·  Drugs  ·  Sponsors  ·  

32 terminated. 32 Phase 2, 6 Phase 3, 4 Phase 1.

By phase and status

PhaseTrialsStatus
Phase 232Terminated 32
Phase 36Terminated 6
Phase 14Terminated 4

Follow Vector Borne Diseases: new trials by email Literature Review of Vector Borne Diseases trials Research Report on Vector Borne Diseases

Trials (filtered) newest first · largest first

All 32 trials

Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.

TrialPhaseStatusSponsorEnrollmentStartUpdated
A Study of JNJ-64281802 for the Prevention of Dengue Infection
JNJ-64281802, Placebo - Dengue
Phase 2TerminatedJanssen Research & Development, LLC15952023-02-222025-07-31
A Study to Determine if New Types of Malaria Vaccines Are Safe, Effective and Lead to Immunity in Kenyan Adults
R21/Matrix-M, ChAd63/MVA ME-TRAP, intradermal injection (ID) or direct venous injection (DVI) of PfSPZ Challenge - Malaria,Falciparum
Phase 2TerminatedUniversity of Oxford802022-08-312025-02-20
Study of AT-752 in Patients With Dengue Infection
AT-752, Placebo - Dengue Fever
Phase 2TerminatedAtea Pharmaceuticals, Inc.212022-04-292024-03-05
A Study of JNJ-64281802 in Participants With Confirmed Dengue Fever
JNJ-64281802, Placebo - Dengue
Phase 2TerminatedJanssen Research & Development, LLC52022-01-242024-03-01
Atorvastatin on Inflammation and Cardiac Function in Chronic Chagas Disease
40 mg Atorvastatin/day for 120 days P.O., Atorvastatin 80, Placebo - Chronic Chagas Disease
Phase 2TerminatedJuan D. Maya3002021-10-122024-09-19
Seamless Controlled Trial To Evaluate Safety And Immunogenicity of Chikungunya Vaccine in LatinAmerica and Asia
BBV87 Chikungunya vaccine, Normal Saline - Chikungunya
Phase 2 / Phase 3TerminatedInternational Vaccine Institute32102021-08-012025-06-22
Study to Assess Adverse Events, Change in Disease Activity and How Oral ABBV-4083 Capsules When Given Alone or In Combination With Albendazole Capsules Moves in The Body of Adult Participants With Onchocerca Volvulus Infection
ABBV-4083, Placebo for ABBV-4083, Albendazole - Onchocerciasis
Phase 2TerminatedAbbVie1532021-05-222024-09-19
Pharmacokinetics, Safety, Tolerability and Efficacy of a New Artemether-lumefantrine Dispersible Tablet in Infants and Neonates <5 kg Body Weight With Acute Uncomplicated Plasmodium Falciparum Malaria
artemether:lumefantrine (2.5 mg:30 mg) - Plasmodium Falciparum Malaria
Phase 2 / Phase 3TerminatedNovartis Pharmaceuticals282020-12-212026-01-13
MMV390048 POC in Patients With P. Vivax and P. Falciparum Malaria
MMV390048 - Malaria
Phase 2TerminatedMedicines for Malaria Venture82017-10-202021-12-09
Evaluation of the Safety of Primaquine in Combination With Dihydroartemisinin-piperaquine in G6PD Deficient Males in The Gambia
Dihydroartemisinin-piperaquine (DHAP) administered to G6PD deficient, Dihydroartemisinin-piperaquine (DHAP) + 0.25 mg/kg primaquine administered to G6PD deficient, Dihydroartemisinin-piperaquine (DHAP) + 0.4 mg/kg primaquine administered to G6PD deficient - Malaria
Phase 2 / Phase 3TerminatedLondon School of Hygiene and Tropical Medicine612015-12-012016-09-09
A Study to Characterise the Antimalarial and Transmission Blocking Activity of a Single Dose of DSM265 or OZ439 in Healthy Subjects With Induced Blood Stage Plasmodium Falciparum or Plasmodium Vivax Infection
DSM265, OZ439 - Malaria
Phase 1 / Phase 2TerminatedMedicines for Malaria Venture162015-10-012020-06-05
Eurartesim® in Patients With Imported Uncomplicated Plasmodium Vivax Malaria
Eurartesim tablets - Malaria, Vivax
Phase 2TerminatedAlfasigma S.p.A.272014-06-182018-09-17
Trial to Determine Efficacy of Fexinidazole in Visceral Leihmaniasis Patients in Sudan
Fexinidazole - Visceral Leishmaniasis
Phase 2TerminatedDrugs for Neglected Diseases142013-11-012015-10-30
Safety, Efficacy, and PK of Topical Paromomycin/Gentamicin Cream for Treatment of Cutaneous Leishmaniasis
WR 279,396 - Leishmaniasis, Cutaneous
Phase 2TerminatedU.S. Army Medical Research and Development Command12013-09-012019-11-22
WR 279,396 Open Label Treatment Protocol in Tunisia
WR 279,396 topical cream - Cutaneous Leishmaniasis
Phase 2TerminatedU.S. Army Medical Research and Development Command502011-12-012014-12-19
Anti-parasitic Activity and Safety Assessment of SAR97276A in Children With Uncomplicated Malaria
SAR97276A, arthemeter + lumefantrine (ACTs) - Malaria
Phase 2TerminatedSanofi202011-10-012012-12-13
Sevuparin/DF02 as an Adjunctive Therapy in Subjects Affected With Uncomplicated Falciparum Malaria
Sevuparin sodium + atovaquone/proquanil, atovaquone/proquanil - Malaria, Falciparum
Phase 1 / Phase 2TerminatedModus Therapeutics AB532011-09-012014-08-19
Phase 1/2a Trial of Pf GAP p52-/p36- Sporozoite Malaria Vaccine
p52-/p36- GAP Vaccine, p52-p36- GAP Vaccine - Malaria
Phase 1 / Phase 2TerminatedSeattle Children's Hospital62010-03-012019-10-28
Vaccine Study for Tick-Borne Encephalitis Virus (TBEV)
FSME-IMMUN 0.5ml Baxter - Tick-Borne Encephalitis, Encephalitis, Tick-Borne
Phase 2TerminatedNational Institute of Allergy and Infectious Diseases (NIAID)692009-09-252018-07-05
Treatment of West Nile Virus With MGAWN1
MGAWN1, Placebo - normal saline - West Nile Neuroinvasive Disease, West Nile Virus Infection
Phase 2TerminatedMacroGenics132009-05-012022-02-10

Showing 20 of 32. Sign in to see all of them.

Narrower conditions

Malaria (9)  ·  Malaria, Falciparum (7)  ·  Leishmaniasis, Cutaneous (5)  ·  Dengue (3)  ·  Leishmaniasis (3)  ·  Leishmaniasis, Visceral (3)  ·  Malaria, Vivax (2)  ·  Chagas Disease (1)  ·  Chikungunya Fever (1)  ·  Encephalitis (1)  ·  Encephalitis, Tick-Borne (1)  ·  Hemorrhagic Fevers, Viral (1)  ·  Infections (1)  ·  Inflammation (1)  ·  Lymphoma, Follicular (1)

Broader conditions

Infections (31)  ·  Parasitic Diseases (26)  ·  Protozoan Infections (25)  ·  Mosquito-Borne Diseases (20)  ·  Euglenozoa Infections (10)  ·  Arbovirus Infections (6)  ·  Malaria (6)  ·  RNA Virus Infections (6)  ·  Skin Diseases (6)  ·  Skin Diseases, Infectious (6)  ·  Skin Diseases, Parasitic (6)  ·  Skin and Connective Tissue Diseases (6)  ·  Flaviviridae Infections (5)  ·  Flavivirus Infections (5)

Interventions

Azithromycin (3)  ·  Chloroquine (3)  ·  Paromomycin (2)  ·  AT-752 (1)  ·  Albendazole (1)  ·  Antimony (1)  ·  Atovaquone (1)  ·  DSM265 (1)  ·  Eflornithine (1)  ·  Injections, Intradermal (1)  ·  Lumefantrine (1)  ·  MMV390048 (1)  ·  Meglumine Antimoniate (1)  ·  Pentoxifylline (1)  ·  Primaquine (1)

Sponsors

U.S. Army Medical Research and Development Command (4)  ·  Drugs for Neglected Diseases (2)  ·  Janssen Research & Development, LLC (2)  ·  Medicines for Malaria Venture (2)  ·  National Institute of Allergy and Infectious Diseases (NIAID) (2)  ·  Pfizer (2)  ·  Sanofi (2)  ·  AB Foundation (1)  ·  AbbVie (1)  ·  Alfasigma S.p.A. (1)  ·  Ana Rabello (1)  ·  Atea Pharmaceuticals, Inc. (1)  ·  Center for Primary Care and Public Health (Unisante), University of Lausanne, Switzerland (1)  ·  Epicentre (1)  ·  Foundation Fader (1)

Countries

Thailand (5)  ·  Brazil (4)  ·  United States (4)  ·  Burkina Faso (3)  ·  Colombia (3)  ·  Kenya (3)  ·  Benin (2)  ·  Democratic Republic of the Congo (2)  ·  Ethiopia (2)  ·  Gabon (2)  ·  Malaysia (2)  ·  Panama (2)  ·  Peru (2)  ·  Philippines (2)  ·  Sudan (2)

Top investigators

Afif Ben Salah, M.D., Ph.D. (1)  ·  Ahmed M Musa, MD PhD (1)  ·  Ana Rabello, MD PhD (1)  ·  Anna Leitgeb, PhD (1)  ·  Blaise Genton, MD, PhD (1)  ·  Christoph Hatz, Prof Dr Med (1)  ·  E. AG Khalil, Prof. MD (1)  ·  Esayas Gudina, MD (1)  ·  Gerardo Priotto, MD MPH (1)

Results publications

PMID 28472957, PMID 21375777, PMID 24029408, PMID 24454970, PMID 29121061, PMID 29244851, PMID 29324864, PMID 30269312, PMID 30858218, PMID 32479608, PMID 34179977, PMID 36509063, PMID 36638112, PMID 41199347, PMID 41495411, PMID 42253092